Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. - Wikidata - wikimedia - TriplyDB

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.

http://www.wikidata.org/entity/Q53061290

about

Prognostic models for chronic lymphocytic leukaemia: an exemplar systematic review and meta-analysis The clinical implications of gene mutations in chronic lymphocytic leukaemia The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond Recurrent mutations refine prognosis in chronic lymphocytic leukemia.Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia Richter transformation of CLL.Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome.Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial.Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients.An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness Predicting treatment outcomes in CLL.Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives.Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood.Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks.MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia.Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?The genomic landscape of chronic lymphocytic leukemia: clinical implications.Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.Developing Molecular Signatures for Chronic Lymphocytic Leukemia.Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia.Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015 Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations Patients' Preferences for Genomic Diagnostic Testing in Chronic Lymphocytic Leukaemia: A Discrete Choice Experiment A Novel Assay for the Identification of NOTCH1 PEST Domain Mutations in Chronic Lymphocytic Leukemia.

P2860

Q24186840-EF75ACAC-1037-4961-AC4E-76162F73E3F1 Q26749214-E19DBEEE-14D3-4422-80A0-82597C5D35FB Q26775506-19B73D96-BD8A-45F9-BFBE-F25F8E9D37EE Q26783600-3CC6B08E-5087-473C-931F-EABDF42C6737 Q26823586-314007CE-36CC-4C61-B6BE-B62FCCF12417 Q27027493-4E6B7116-9E80-4E4B-A75B-B9D7F85C33D2 Q27853022-5FDEB821-785A-4A94-8DDB-8DCCB78F835E Q27853333-E65E9FC6-6DD4-4AB5-8576-F6671650D025 Q28077136-364D28D8-CA23-4AE5-9DAA-76C12F2C9D57 Q28087672-C6CE7A4A-B4D0-479A-B0B8-BC42CC63E9CC Q30249283-17D1BF86-85EA-477C-85F3-331257673BE7 Q30833823-59F0F889-A2BD-4597-ACF3-775F9D2FD19E Q31056968-EAC7C7F8-B5B4-4160-8126-F8CE6A8C628B Q33419580-55D4F664-4611-47B4-827F-E2FD23D58E23 Q33438825-41EC5F84-5FA4-467E-87C6-3F71028EF47E Q33648906-0A0E9CBA-A87F-47B8-A992-54C93DC96D90 Q33709543-FB85428E-1227-4688-94FD-B1D76AA33A8A Q33714743-5907193B-9B8A-4234-9E1C-E60290E0A2C9 Q33729711-DF02AE82-DD0B-49E3-B270-2A3EE57DD253 Q33774491-9C6496EA-4E88-4084-ABC6-0E4A371D0ED4 Q33862792-5E072CFF-B310-4FE4-BB6A-5420C54D82DF Q33869257-707AFAEB-02D0-4564-ADF6-1BD864F17AF8 Q33880538-D252C850-9B44-46B1-AA11-01B5D4F28A3B Q33913537-0513B064-4893-45D3-B16F-93514B8550F4 Q34625543-810D1F4E-6412-48DC-A963-9FE49565BE04 Q34710882-73E59672-373E-4C5D-9E9F-A5E3AF993CDF Q35146301-94B32E76-637D-48F4-A54F-7BC58390FD5B Q35653850-E33830ED-8676-49D6-9C27-AE48F4CCFAF7 Q35741703-7AB67CD9-3112-43F8-9DB0-80B030E36C31 Q35958056-BCBD2311-D6E0-4F46-B3CE-1E0E10A19A49 Q35984259-4F17AE53-E77B-4578-88B9-4A848224DB33 Q36326271-768C4083-3865-4C2F-BEE6-1B2B0CAAF4DD Q36471596-D482FB9B-DD31-40F3-9EC5-FE5C1D324803 Q36550468-9D44B21D-79C8-481D-BB03-67815ACA4AB3 Q36782516-38D06518-D099-4B54-9EEC-5A91277497E3 Q36826893-2FD40F9E-BB1F-40EA-BDC3-5C66B69A581A Q36884141-9083D48F-6BE8-470C-997F-A253431317F0 Q37260520-0F1401AD-78AB-4659-A179-799DADC166C5 Q37410709-EA8C8C48-5288-4FB7-94B2-94F3BF27F99F Q37542431-56779272-F797-4433-B625-350FC1C9666D

P2860

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.

http://www.wikidata.org/entity/Q53061290

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Gene mutations and treatment o ...... : results from the CLL8 trial.

@en

Gene mutations and treatment o ...... : results from the CLL8 trial.

@nl

type

label

Gene mutations and treatment o ...... : results from the CLL8 trial.

@en

Gene mutations and treatment o ...... : results from the CLL8 trial.

@nl

prefLabel

Gene mutations and treatment o ...... : results from the CLL8 trial.

@en

Gene mutations and treatment o ...... : results from the CLL8 trial.

@nl

P1433

Q53061290-76CCB8E6-EA28-456C-AFE2-436D7E293B73

P1476

Q53061290-0E4D0FC5-F5D2-4A8A-9A97-4C968915E3F4

P2093

Q53061290-081D537A-56D6-4FBD-A36A-CAFC17AABF3F

Q53061290-0A291DBA-215F-4C7E-9A2D-200D64630780

Q53061290-0BADAAA9-9A3A-42F8-92D3-472CF9BC516E

Q53061290-0C2D1F97-0441-43E6-8B0B-E24E532F6CAB

Q53061290-1870844D-4F11-4B1E-82ED-2FEE4E5FD56B

Q53061290-24C3D7FE-B429-4A48-B74F-A849C5B4C26D

Q53061290-37469902-420D-42AB-946A-32871E35AD08

Q53061290-3CEAFB6F-122D-455F-B562-1414F4A86A82

Q53061290-3D7CC3DF-2B5E-499A-B162-94485E63F06E

Q53061290-4BD0F82C-B1FB-4073-A988-E4DB0DA747EC

P304

Q53061290-1353F264-D199-484C-9732-B76051101083

P31

Q53061290-04E7BE99-892A-41E0-B448-88C02D9DFE6A

P356

Q53061290-35DC7359-70F7-4F01-81E1-C25860049763

P407

Q53061290-77184854-F4BB-4500-A685-C5BB86C26CE4

P433

Q53061290-5661ED05-EDB3-4B70-8ADB-C2BBD3BE2222

P478

Q53061290-18D5859E-EA11-41C0-A3A7-BE1609B29D2A

P50

Q53061290-4269A268-E33A-4872-A745-8C487D5800AF

Q53061290-54112B6B-3450-4EF9-9F42-47C59A555572

Q53061290-9E23D7DE-3225-43C7-AD3C-CED5C3370536

Q53061290-BD436F5C-F285-4A09-8C84-F8DE9901B9B7

Q53061290-FB1707AA-3763-4A04-B0FA-33F78E3B1247

P577

Q53061290-63AC1292-8D9F-4745-B467-F5E1D56FA386

P5875

Q53061290-AFC8D9C5-04BA-407C-944C-AD148D5028E8

P698

Q53061290-B7597479-1321-4D0D-A884-3DE508480A7A

P921

Q53061290-9687E71D-1B9D-4082-957D-99AE40F2F8F3

Q53061290-A7DDB642-F231-4696-A456-550F7579FBD4

P356

BLOOD-2014-01-546150

P1433

P1476

Gene mutations and treatment o ...... : results from the CLL8 trial.

@en

P2093

Andrea Schnaiter

http://www.w3.org/2001/XMLSchema#string

Andreas Bühler

http://www.w3.org/2001/XMLSchema#string

Anna M Fink

http://www.w3.org/2001/XMLSchema#string

Clemens M Wendtner

http://www.w3.org/2001/XMLSchema#string

Daniel Mertens

http://www.w3.org/2001/XMLSchema#string

Dirk Winkler

http://www.w3.org/2001/XMLSchema#string

Eugen Tausch

http://www.w3.org/2001/XMLSchema#string

Günter Fingerle-Rowson

http://www.w3.org/2001/XMLSchema#string

Jennifer Edelmann

http://www.w3.org/2001/XMLSchema#string

Kirsten Fischer

http://www.w3.org/2001/XMLSchema#string

P304

3247-3254

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2014-01-546150

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

Hartmut Döhner

Konstanze Döhner

P577

2014-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260999112

http://www.w3.org/2001/XMLSchema#string

P698

24652989

http://www.w3.org/2001/XMLSchema#string

P921